Current Hematologic Malignancy Reports

, Volume 14, Issue 3, pp 137–144 | Cite as

Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

  • Alain Antoine Mina
  • Brady SteinEmail author
Myeloproliferative Neoplasms (B Stein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Myeloproliferative Neoplasms


Purpose of review

To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response.

Recent findings

Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognostic models that predict disease course have therefore been developed. In myelofibrosis, this has led to a more nuanced prognostic assessment which is a necessary tool for the identification of potential transplant patients. The extended molecular profile may also help set expectations for ruxolitinib response duration. In essential thrombocythemia and polycythemia vera, elucidation of the molecular landscape beyond driving mutations may identify patients at risk for more rapid progression. However, results from testing are less likely to lead to action, at least in the current era.


Use of next-generation sequencing has become routine in myelofibrosis, as a means of identifying patients at highest risk for progression, who may be eligible for transplantation. Extended genetic sequencing is still investigational in essential thrombocytosis and polycythemia vera, and not recommended by guidelines.


Myeloproliferative neoplasms Next-generation sequencing Polycythemia vera Essential thrombocythemia Myelofibrosis 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Xia D, Hasserjian RP. Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. Am J Hematol. 2016;91:1277–80. Scholar
  2. 2.
    Chang YC, Lin HC, Chiang YH, et al. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017.
  3. 3.
    Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005.
  4. 4.
    Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016.
  5. 5.
    Aaronson DS, Horvath CM. A road map for those who do not know JAK-STAT. Science. 2002;(80).
  6. 6.
    Christian Pecquet, Thomas Balligand, Ilyas Chachoua, Anita Roy, Gaelle Vertenoeil, Didier Colau, Emanuel Fertig, Caroline Marty, Harini Nivarthi, Jean-Philippe Defour, Erica Xu, Eva Hug, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Carol and SNC (2018) 4 Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: Perspectives for MPN Therapy.Google Scholar
  7. 7.
    Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014.,136.
  8. 8.
    Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015.
  9. 9.
    Broséus J, Park J-H, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014;124:3964–6.CrossRefGoogle Scholar
  10. 10.
    Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, et al. Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Investig. 2016.
  11. 11.
    Kang M-G, Choi H-W, Lee JH, Choi YJ, Choi H-J, Shin J-H, et al. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016;7:57036–57,049.Google Scholar
  12. 12.
    Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms. Mayo Clin Proc. 2017.
  13. 13.
    Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–9.CrossRefGoogle Scholar
  14. 14.
    Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013.
  15. 15.
    Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood. 2009.,449.
  16. 16.
    Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014.
  17. 17.
    Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014.
  18. 18.
    Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014.
  19. 19.
    Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, et al. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia. 2015.
  20. 20.
    Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016.
  21. 21.
    Thoennissen NH, Krug UO, Lee DHT, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010.,119.
  22. 22.
    Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012.,252.
  23. 23.
    Singh NR. Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis. Transl Pediatr. 2015.
  24. 24.
    •• Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018. The rise of new prognostic scoring systems that revolve around molecular profiling in addition to clinical data.
  25. 25.
    Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017.
  26. 26.
    Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS701 version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018.
  27. 27.
    • Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014.,557. Beyond prognostication, genetic testing predicting treatment responses (to ruxolitinib) in MF.
  28. 28.
    Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in Myelofibrosis. N Engl J Med. 2010.
  29. 29.
    • Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015.,404. Beyond treatment responses, mutational profile and ts association with spleen size and time to treatment discontinuation.
  30. 30.
    Spiegel JY, McNamara C, Kennedy JA, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv. 2017.
  31. 31.
    Pacilli A, Rotunno G, Mannarelli C, et al. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. 8:122.Google Scholar
  32. 32.
    Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017.,225.
  33. 33.
    Luque Paz D, Chauveau A, Boyer F, et al. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosom Cancer. 2017.
  34. 34.
    Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosom Cancer. 2012.
  35. 35.
    Delhommeau F, Dupont S, Valle V Della, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009.
  36. 36.
    Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014.,167.
  37. 37.
    Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008.,748.
  38. 38.
    Alvarez-Larrán A, Bellosillo B, Pereira A, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014.
  39. 39.
    Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. P53 lesions in leukemic transformation. N Engl J Med. 2011.
  40. 40.
    Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601–12.CrossRefGoogle Scholar
  41. 41.
    • Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016. One of the largest studies to look into mutational profile in patients with PV and ET.
  42. 42.
    • Senín A, Fernández-Rodríguez C, Bellosillo B, Camacho L, Longarón R, Angona A, et al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol. 2018. Study underlying the association between non driver mutations and clinical outcomes/transformation in PV and ET patients.
  43. 43.
    •• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013.,012. Extended genetic makeup defining treatment responses in ET and PV to Pegylated alpha-2a
  44. 44.
    Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015.,060.
  45. 45.
    •• Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018. Grinfeld identifying 8 distinct genetic subgroups in one of the largest cohorts ever studied in MPNs and correlating each subgroup with a distinct clinical course.
  46. 46.
    Mesa RA, Jamieson C, Bhatia R, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Cancer Netw. 2017;15:1193–207.CrossRefGoogle Scholar
  47. 47.
    Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineNorthwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer CenterChicagoUSA
  2. 2.ChicagoUSA

Personalised recommendations